Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference
10 sept. 2020 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock
18 août 2020 09h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
12 août 2020 21h37 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock
11 août 2020 16h01 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results
10 août 2020 16h00 HE
|
Adverum Biotechnologies, Inc.
-- Continued robust treatment response from both high and low doses -- -- Long-term durability beyond 15 months from single IVT injection with zero rescue injections in Cohort 1 -- -- Well...
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update
29 juil. 2020 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy
21 juil. 2020 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME)
13 juil. 2020 08h30 HE
|
Adverum Biotechnologies, Inc.
-- INFINITY trial is currently enrolling patients with DME, the most common cause of vision loss in people with diabetic retinopathy -- REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) --...
Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD
06 juil. 2020 09h00 HE
|
Adverum Biotechnologies, Inc.
-- Patients in Cohort 4 received ADVM-022 high dose 6x1011 vg and prophylactic steroid eye drops -- -- Data from all four cohorts planned by the end of 2020 -- REDWOOD CITY, Calif., July 06, 2020 ...
Adverum Biotechnologies Announces Appointment of Heikki Jouttijärvi as Vice President of Manufacturing
25 juin 2020 16h01 HE
|
Adverum Biotechnologies, Inc.
-- Plans underway to begin expansion of manufacturing capabilities -- REDWOOD CITY, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene...